Skip to content
2000
image of Managing Drug Interactions between Antiretrovirals and Opportunistic Infections in People with HIV

Abstract

Introduction

While care for people with HIV has significantly improved, opportunistic infections remain a risk for patients. Antiretrovirals can interact with the drugs used to treat opportunistic infections, and care must be taken to minimize these interactions.

Methodology

We completed a narrative review of medications to treat opportunistic infections in people with HIV and antiretrovirals.

Results

Here we review the risks of opportunistic infections, most notably hepatitis B, hepatitis C, tuberculosis, cryptococcal meningitis, and pneumocystis pneumonia, in people with HIV, including known and potential interactions between antiretrovirals and the treatments for opportunistic infections, and the mechanisms of these interactions. We also discuss immune reconstitution inflammatory syndrome, an inflammatory response due to immune rebound, which can occur in people treated with antiretrovirals, particularly in patients who have active opportunistic infections.

Discussion

While the risk of IRIS has decreased for many opportunistic infections, it can still occur, particularly in patients who are infected with . Treating opportunistic infections in people with HIV requires considerable care and expertise.

Conclusion

While advancements in care have simplified treatment for these patients, there is still a considerable risk of interactions between antiretrovirals and opportunistic infections, as well as the drugs used to treat them. Future strategies, including newer agents, regimen simplification, and comprehensive management strategies, can further decrease the risk of interactions between antiretrovirals and opportunistic infection agents, as well as further decrease the risk of IRIS.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X419952251030045143
2026-01-22
2026-01-29

  • From This Site

    /content/journals/chr/10.2174/011570162X419952251030045143
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Paudel M. Prajapati G. Buysman E.K. Comorbidity and comedication burden among people living with HIV in the United States. Curr. Med. Res. Opin. 2022 38 8 1443 1450 10.1080/03007995.2022.2088714 35757905
    [Google Scholar]
  2. Dagnaw Tegegne K. Cherie N. Tadesse F. Tilahun L. Kassaw M.W. Biset G. Incidence and predictors of opportunistic infections among adult HIV infected patients on anti-retroviral therapy at dessie comprehensive specialized hospital, ethiopia: A retrospective follow-up study. HIV AIDS 2022 14 195 206 10.2147/HIV.S346182 35469324
    [Google Scholar]
  3. Kouanfack O.S.D. Kouanfack C. Billong S.C. Epidemiology of opportunistic infections in HIV infected patients on treatment in accredited hiv treatment centers in cameroon. Int. J. MCH AIDS 2019 8 2 163 172 10.21106/ijma.302 32257607
    [Google Scholar]
  4. HIV/AIDS treatment guidelines. 2024 Available from: ] https://clinicalinfo.hiv.gov/en/guidelines
  5. Tewachew A.S. Mekonnen W.N. Mekuria A.D. Amare Y.E. Determinants of opportunistic infections among hiv-positive patients on HAART in Debre Berhan referral hospital, North Shoa Zone, Ethiopia, 2020: A case-control study. HIV AIDS 2021 13 337 347 10.2147/HIV.S298661 33824603
    [Google Scholar]
  6. Custer S.S. Management of coinfections in patients with human immunodeficiency virus. Nurs. Clin. North Am. 2018 53 1 83 96 10.1016/j.cnur.2017.10.001 29362063
    [Google Scholar]
  7. Eneh P.C. Hullsiek K.H. Kiiza D. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda. BMC Infect. Dis. 2020 20 1 572 10.1186/s12879‑020‑05296‑w 32758158
    [Google Scholar]
  8. Zhao A.V. Crutchley R.D. Guduru R.C. Ton K. Lam T. Min A.C. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. Retrovirology 2022 19 1 22 10.1186/s12977‑022‑00608‑1 36273165
    [Google Scholar]
  9. Vivithanaporn P. Kongratanapasert T. Suriyapakorn B. Potential drug-drug interactions of antiretrovirals and antimicrobials detected by three databases. Sci. Rep. 2021 11 1 6089 10.1038/s41598‑021‑85586‑8 33731842
    [Google Scholar]
  10. Doan J. Brunzo-Hager S. Satterly B. Cory T.J. Expanding therapeutic options: Lenacapavir + bictegravir as a potential treatment for HIV. Expert Opin. Pharmacother. 2023 24 18 1949 1956 10.1080/14656566.2023.2294918 38164956
    [Google Scholar]
  11. Ratnam I. Chiu C. Kandala N.B. Easterbrook P.J. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin. Infect. Dis. 2006 42 3 418 427 10.1086/499356 16392092
    [Google Scholar]
  12. DeSimone J.A. Pomerantz R.J. Babinchak T.J. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann. Intern. Med. 2000 133 6 447 454 10.7326/0003‑4819‑133‑6‑200009190‑00013 10975963
    [Google Scholar]
  13. Bosamiya S. The immune reconstitution inflammatory syndrome. Indian J. Dermatol. 2011 56 5 476 479 10.4103/0019‑5154.87114 22121257
    [Google Scholar]
  14. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. 2024 Available from:https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/toxoplasmosis
  15. Vinhaes C.L. Araujo-Pereira M. Tibúrcio R. Systemic inflammation associated with immune reconstitution inflammatory syndrome in persons living with HIV. Life 2021 11 1 65 10.3390/life11010065 33477581
    [Google Scholar]
  16. Armange L. Lacroix A. Petitgas P. The use of TNF-α antagonists in tuberculosis to control severe paradoxical reaction or immune reconstitution inflammatory syndrome: A case series and literature review. Eur. J. Clin. Microbiol. Infect. Dis. 2023 42 4 413 422 10.1007/s10096‑023‑04564‑2 36795280
    [Google Scholar]
  17. Hepatitis B. 2024 World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
    [Google Scholar]
  18. HIV data and statistics. 2024 World Health Organization. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
    [Google Scholar]
  19. HIV/AIDS coinfection. 2024 Hepatitis B Foundation. Available from: https://www.hepb.org/what-is-hepatitis-b/hivaids-co-infection/
    [Google Scholar]
  20. Smolders E.J. Burger D.M. Feld J.J. Kiser J.J. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment. Pharmacol. Ther. 2020 51 2 231 243 10.1111/apt.15581 31840863
    [Google Scholar]
  21. Organization W.H. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. World Health Organization 2024
    [Google Scholar]
  22. Terrault N.A. Bzowej N.H. Chang K.M. Hwang J.P. Jonas M.M. Murad M.H. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016 63 1 261 283 10.1002/hep.28156 26566064
    [Google Scholar]
  23. HIV drug interactions. 2025. University of Liverpool. Available from: https://hiv-druginteractions.org/checker
  24. Hepatitis C. 2024 World Health Organization. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
    [Google Scholar]
  25. Recommendations for testing, managing, and treating Hepatitis C 2022 AASLD-IDSA Available from: http://www.hcvguidelines.org
    [Google Scholar]
  26. Gao L-H. Nie Q-H. Zhao X-T. Drug-drug interactions of newly approved direct-acting antiviral agents in patients with Hepatitis C. Int. J. Gen. Med. 2021 14 289 301 10.2147/IJGM.S283910 33536776
    [Google Scholar]
  27. Néant N. Solas C. Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection. Int. J. Antimicrob. Agents 2020 56 1 105571 10.1016/j.ijantimicag.2018.10.014 30394302
    [Google Scholar]
  28. Liverpool H.E.P. Interactions 2025 Available from: https://www.hep-druginteractions.org/checker
  29. lobal Tuberculosis report 2023 2023.W.H.O. Available from: https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-reports/global-tuberculosis-report-2023-
    [Google Scholar]
  30. Cerrone M. Bracchi M. Wasserman S. Safety implications of combined antiretroviral and anti-tuberculosis drugs. Expert Opin. Drug Saf. 2020 19 1 23 41 10.1080/14740338.2020.1694901 31809218
    [Google Scholar]
  31. Treating Tuberculosis 2024 Centers for Disease Control. Available from: https://www.cdc.gov/tb/treatment/index.html
    [Google Scholar]
  32. Meintjes G. Brust J.C.M. Nuttall J. Maartens G. Management of active tuberculosis in adults with HIV. Lancet HIV 2019 6 7 e463 e474 10.1016/S2352‑3018(19)30154‑7 31272663
    [Google Scholar]
  33. Nahid P. Dorman S.E. Alipanah N. Official American Thoracic Society/Centers for disease control and prevention/infectious diseases Society of America Clinical Practice Guidelines: Treatment of drug-susceptible tuberculosis. Clin. Infect. Dis. 2016 63 7 e147 e195 10.1093/cid/ciw376 27516382
    [Google Scholar]
  34. 2024 Available from: https://www.biktarvyhcp.com/
  35. emlidy® (tenofovir alafenamide) tablets, for oral use. 2016.Tenofo-vir Alafenamide Prescribing Information 2024 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208464s000lbl.pdf
  36. Pooranagangadevi N. Padmapriyadarsini C. Treatment of Tuberculosis and the drug interactions associated with HIV-TB co-infection treatment. Front. Trop. Dis. 2022 3 10.3389/fitd.2022.834013
    [Google Scholar]
  37. Custodio J.M. West S.K. Vu A. Pharmacokinetics of bictegravir administered twice daily in combination with rifampin. Program and abstracts of the 2018 Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts March 4-7, 2018
    [Google Scholar]
  38. Resende N.H.D. Pantuzza L.L.N. Carvalho W.D.S. Miranda S.S.D. Laper I.Z. Reis A.M.M. Efficacy, effectiveness, and safety of integrase inhibitors in the treatment of HIV/AIDS in patients with tuberculosis: Systematic review and meta-analysis. Res Soc Dev 2022 11 10 e174111032636
    [Google Scholar]
  39. De Castro N. Marcy O. Chazallon C. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): An open-label, non-inferiority, randomised, phase 3 trial. Lancet Infect. Dis. 2021 21 6 813 822 10.1016/S1473‑3099(20)30869‑0 33667406
    [Google Scholar]
  40. De Nicolò A. Calcagno A. Motta I. The effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within peripheral blood mononuclear cells: A dose escalation study. Antimicrob. Agents Chemother. 2022 66 6 e00136 e22 10.1128/aac.00136‑22 35583344
    [Google Scholar]
  41. Marc W. Benator D. Peloquin C.A. Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. Clin. Infect. Dis. 2005 41 9 1343 1349 10.1086/496980 16206114
    [Google Scholar]
  42. Sekar V. Lavreys L. Van de Casteele T. Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers. Antimicrob. Agents Chemother. 2010 54 10 4440 4445 10.1128/AAC.01749‑09 20660678
    [Google Scholar]
  43. Decloedt E.H. McIlleron H. Smith P. Merry C. Orrell C. Maartens G. Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob. Agents Chemother. 2011 55 7 3195 3200 10.1128/AAC.01598‑10 21537021
    [Google Scholar]
  44. Beishuizen S.J. Geerlings S.E. Immune reconstitution inflammatory syndrome: Immunopathogenesis, risk factors, diagnosis, treatment and prevention. Neth. J. Med. 2009 67 10 327 331 [PMID: 19915226
    [Google Scholar]
  45. Gangcuangco L.M.A. Sawada I. Tsuchiya N. Regional differences in the prevalence of major opportunistic infections among antiretroviral-naïve human immunodeficiency virus patients in Japan, Northern Thailand, Northern Vietnam, and the Philippines. Am. J. Trop. Med. Hyg. 2017 97 1 49 56 10.4269/ajtmh.16‑0783 28719295
    [Google Scholar]
  46. Muzazu S.G.Y. Assefa D.G. Phiri C. Prevalence of Cryptococcal Meningitis among people living with human immuno-deficiency virus and predictors of mortality in adults on induction therapy in Africa: A systematic review and meta-analysis. Front. Med. (Lausanne) 2022 9 989265 10.3389/fmed.2022.989265 36160163
    [Google Scholar]
  47. Molloy S.F. Kanyama C. Heyderman R.S. Antifungal combinations for treatment of Cryptococcal Meningitis in Africa. N. Engl. J. Med. 2018 378 11 1004 1017 10.1056/NEJMoa1710922 29539274
    [Google Scholar]
  48. Lawrence D.S. Boyer-Chammard T. Jarvis J.N. Emerging concepts in HIV-associated Cryptococcal Meningitis. Curr. Opin. Infect. Dis. 2019 32 1 16 23 10.1097/QCO.0000000000000514 30507673
    [Google Scholar]
  49. Ssebambulidde K. Bangdiwala A.S. Kwizera R. Symptomatic Cryptococcal Antigenemia presenting as early Cryptococcal Meningitis with negative cerebral spinal fluid analysis. Clin. Infect. Dis. 2019 68 12 2094 2098 10.1093/cid/ciy817 30256903
    [Google Scholar]
  50. 2024 https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/cryptococcosis?view=full
  51. van der Horst C.M. Saag M.S. Cloud G.A. Treatment of Cryptococcal Meningitis associated with the acquired immunodeficiency syndrome. N. Engl. J. Med. 1997 337 1 15 21 10.1056/NEJM199707033370103 9203426
    [Google Scholar]
  52. Vermes A. Guchelaar H.J. Dankert J. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 2000 46 2 171 179 10.1093/jac/46.2.171 10933638
    [Google Scholar]
  53. Loyse A. Dromer F. Day J. Lortholary O. Harrison T.S. Flucytosine and cryptococcosis: Time to urgently address the worldwide accessibility of a 50-year-old antifungal. J. Antimicrob. Chemother. 2013 68 11 2435 2444 10.1093/jac/dkt221 23788479
    [Google Scholar]
  54. Sigera L.S.M. Denning D.W. Flucytosine and its clinical usage. Ther. Adv. Infect. Dis. 2023 10 20499361231161387 10.1177/20499361231161387 37051439
    [Google Scholar]
  55. Kneale M. Bartholomew J.S. Davies E. Denning D.W. Global access to antifungal therapy and its variable cost. J. Antimicrob. Chemother. 2016 71 12 3599 3606 10.1093/jac/dkw325 27516477
    [Google Scholar]
  56. Laniado-Laborín R. Cabrales-Vargas M.N. Amphotericin B. Side effects and toxicity. Rev. Iberoam. Micol. 2009 26 4 223 227 10.1016/j.riam.2009.06.003 19836985
    [Google Scholar]
  57. Kiggundu R. Morawski B.M. Bahr N.C. Brief Report. J. Acquir. Immune Defic. Syndr. 2016 71 1 65 69 10.1097/QAI.0000000000000812 26334743
    [Google Scholar]
  58. Milsap D. Okuno M. Kigozi E. Induction treatment for HIV-Associated Cryptococcal Meningitis: Where have we been and where are we going? Microorganisms 2025 13 4 847 10.3390/microorganisms13040847 40284683
    [Google Scholar]
  59. Vadlapatla R.K. Patel M. Paturi D.K. Pal D. Mitra A.K. Clinically relevant drug–drug interactions between antiretrovirals and antifungals. Expert Opin. Drug Metab. Toxicol. 2014 10 4 561 580 10.1517/17425255.2014.883379 24521092
    [Google Scholar]
  60. uidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024 Available from: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf-
  61. Gong Y. Haque S. Chowdhury P. Pharmacokinetics and pharmacodynamics of cytochrome P450 inhibitors for HIV treatment. Expert Opin. Drug Metab. Toxicol. 2019 15 5 417 427 10.1080/17425255.2019.1604685 30951643
    [Google Scholar]
  62. Lai R.P.J. Nakiwala J.K. Meintjes G. Wilkinson R.J. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur. J. Immunol. 2013 43 8 1995 2002 10.1002/eji.201343632 23928963
    [Google Scholar]
  63. Chang C.C. Dorasamy A.A. Gosnell B.I. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS 2013 27 13 2089 2099 10.1097/QAD.0b013e3283614a8d 23525034
    [Google Scholar]
  64. Boulware D.R. Bonham S.C. Meya D.B. Paucity of initial cerebrospinal fluid inflammation in Cryptococcal Meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 2010 202 6 962 970 10.1086/655785 20677939
    [Google Scholar]
  65. Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV. 2022 W.H.O. Available from:https://www.who.int/citations/i/item/9789240052178-
    [Google Scholar]
  66. Brienze V.M.S. André J.C. Liso E. Louis I.V. Cryptococcal immune reconstitution inflammatory syndrome: From blood and cerebrospinal fluid biomarkers to treatment approaches. Life 2021 11 2 95 10.3390/life11020095 33514007
    [Google Scholar]
  67. Sidrim J.J.C. Perdigão-Neto L.V. Cordeiro R.A. Viral protease inhibitors affect the production of virulence factors in Cryptococcus neoformans. Can. J. Microbiol. 2012 58 7 932 936 10.1139/w2012‑075 22716223
    [Google Scholar]
  68. Monari C. Pericolini E. Bistoni G. Cenci E. Bistoni F. Vecchiarelli A. Influence of indinavir on virulence and growth of Cryptococcus neoformans. J. Infect. Dis. 2005 191 2 307 311 10.1086/426828 15609242
    [Google Scholar]
  69. Blasi E. Colombari B. Francesca Orsi C. The human immunodeficiency virus (HIV) protease inhibitor indinavir directly affects the opportunistic fungal pathogen Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 2004 42 2 187 195 10.1016/j.femsim.2004.05.001 15364103
    [Google Scholar]
  70. Gutierrez-Gongora D. Geddes-McAlister J. From naturally-sourced protease inhibitors to new treatments for fungal infections. J. Fungi 2021 7 12 1016 10.3390/jof7121016 34946998
    [Google Scholar]
  71. Alkashef N.M. Seleem M.N. Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B’s antifungal efficacy in cryptococcosis. PLoS One 2024 19 8 e0308216 10.1371/journal.pone.0308216 39088434
    [Google Scholar]
  72. Truong J. Ashurst J.V. Pneumocystis jirovecii pneumonia StatPearls. StatPearls Publishing. Internet 2023
    [Google Scholar]
  73. Eisenhauer M.D. Eliasson A.H. Taylor A.J. Coyne P.E. Wortham D.C. Incidence of cardiac arrhythmias during intravenous pentamidine therapy in HIV-infected patients. Chest 1994 105 2 389 395 10.1378/chest.105.2.389 8306734
    [Google Scholar]
  74. Cortese L.M. Gasser R.A. Bjornson D.C. Dacey M.J. Oster C.N. Prolonged recurrence of pentamidine-induced torsades de pointes. Ann. Pharmacother. 1992 26 11 1365 1369 10.1177/106002809202601104 1477438
    [Google Scholar]
  75. Girgis I. Gualberti J. Langan L. A prospective study of the effect of I.V. pentamidine therapy on ventricular arrhythmias and QTc prolongation in HIV-infected patients. Chest 1997 112 3 646 653 10.1378/chest.112.3.646 9315796
    [Google Scholar]
  76. Chastain D.B. Veve M.P. Wagner J.L. Abnormal QTc syndrome in HIV-infected patients: A systematic review of prevalence and risk factors. Antivir. Ther. 2019 24 6 459 465 10.3851/IMP3335 31570667
    [Google Scholar]
  77. Jens D.L. Abdel G.B. Fred G. Sean E. Birgit G. Shweta S. Anchalee A. David A.C. Gerd F. Josep M.L. Jean-Michel M. Paula M. Mauro S. Robin W. Karin L.K. Simon C. H Clifford L, Andrew N P, James D N. Reyataz® Package insert 2018. Princeton, NJ, USA Bristol-Myers Squibb Company 2018
    [Google Scholar]
  78. Jens D.L. Abdel G.B. Fred G. Sean E. Birgit G. Shweta S. Anchalee A. David A.C. Gerd F. Josep M.L. Jean-Michel M. Paula M. Mauro S. Robin W. Karin L.K. Simon C. H Clifford L, Andrew N P, James D N. Initiation of antiretroviral therapy in early asymptomatic hiv infec-tion. N. Engl. J. Med. 2015 373 9 795 807 10.1056/NEJMoa1506816 26192873
    [Google Scholar]
  79. Sandul A.L. Rapposelli K. Nyendak M. Kim M. Updated recommendation for universal Hepatitis B vaccination in adults aged 19-59 years - United States, 2024. MMWR Morb. Mortal. Wkly. Rep. 2024 73 48 1106 10.15585/mmwr.mm7348a3 39636783
    [Google Scholar]
  80. Bernard M. Handsfield H.H. Lampe M.A. Janssen R.S. Taylor A.W. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm. Rep. 2006 55 RR-14 1 17 [PMID: 16988643
    [Google Scholar]
  81. Ankomah A. Ganle J.K. Lartey M.Y. ART access-related barriers faced by HIV-positive persons linked to care in southern Ghana: A mixed method study. BMC Infect. Dis. 2016 16 1 738 10.1186/s12879‑016‑2075‑0 27927183
    [Google Scholar]
  82. Seid A. Seid O. Workineh Y. Dessie G. Bitew Z.W. Prevalence of undernutrition and associated factors among adults taking antiretroviral therapy in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One 2023 18 3 e0283502 10.1371/journal.pone.0283502 36961844
    [Google Scholar]
  83. Papageorgiou V. Davies B. Cooper E. Singer A. Ward H. Influence of material deprivation on clinical outcomes among people living with HIV in high-income countries: A systematic review and meta-analysis. AIDS Behav. 2022 26 6 2026 2054 10.1007/s10461‑021‑03551‑y 34894331
    [Google Scholar]
  84. Nachega J.B. Adetokunboh O. Uthman O.A. Community-based interventions to improve and sustain antiretroviral therapy adherence, retention in HIV care and clinical outcomes in low- and middle-income countries for achieving the UNAIDS 90-90-90 targets. Curr. HIV/AIDS Rep. 2016 13 5 241 255 10.1007/s11904‑016‑0325‑9 27475643
    [Google Scholar]
  85. Bekker L.G. Alleyne G. Baral S. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: The International AIDS Society—Lancet Commission. Lancet 2018 392 10144 312 358 10.1016/S0140‑6736(18)31070‑5 30032975
    [Google Scholar]
/content/journals/chr/10.2174/011570162X419952251030045143
Loading

  • Article Type:     Review Article
Keywords: antiretroviral ; antiviral ; antifungal ; opportunistic infection ; antibiotic ; HIV

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test